AstraZeneca: shares up after UBS raises target price
(CercleFinance.com) - Shares in AstraZeneca are amongst the top gainers of the FTSE 100 index on Monday, up 0.
7% at 5,265 pence, after UBS raised its target price for the share to 5,600 pence, from 4,550 pence.
UBS - which has a "neutral" rating on the stock - said in a report that it sees Astra's Tagrisso representing over 5 billion dollars in revenue by 2022 after two new patient flow analyses showed the cancer drug's market share potential.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
7% at 5,265 pence, after UBS raised its target price for the share to 5,600 pence, from 4,550 pence.
UBS - which has a "neutral" rating on the stock - said in a report that it sees Astra's Tagrisso representing over 5 billion dollars in revenue by 2022 after two new patient flow analyses showed the cancer drug's market share potential.
Copyright (c) 2018 CercleFinance.com. All rights reserved.